HPV Associated Disorders Market Report 2026
Global Outlook – By Indication (Cervical Intraepithelial Neoplasia (CIN), Cervical Cancer, Anal Intraepithelial Neoplasia (AIN), Anal Cancer, Genital Warts, Other Indications), By Therapy (Prevention, Treatment), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, Strategies, and Forecast to 2030
HPV Associated Disorders Market Overview
• HPV Associated Disorders market size has reached to $22.13 billion in 2025 • Expected to grow to $30.97 billion in 2030 at a compound annual growth rate (CAGR) of 6.9% • Growth Driver: Rising Prevalence Of HPV-Associated Cases To Drive HPV Associated Disorders Market • Market Trend: Gender-Neutral HPV Vaccine To Combat HPV-Related Diseases • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under HPV Associated Disorders Market?
The human papillomavirus-associated disorders refer to a virus that can induce aberrant tissue growth such as warts and other cell abnormalities. These disorders are mainly transmitted by sexual intercourse or other forms of skin-to-skin contact. Vaccines, medication, and other diagnoses can help protect against HPV types that cure HPV cancer. The main indication of HPV-associated disorders are cervical intraepithelial neoplasia (CIN), cervical cancer, anal intraepithelial neoplasia (AIN), anal cancer, genital warts, and others indication. The cervical intraepithelial indication of HPV-associated disorder is used for the prevention and treatment of cervical intraepithelial neoplasia. Cervical intraepithelial neoplasia (CIN) refers to abnormal alterations in the cells that line the cervix. The therapy of HPV-associated disorders is prevention and treatment which are provided by hospital pharmacies, retail pharmacies, and online pharmacies.
What Is The HPV Associated Disorders Market Size and Share 2026?
The hpv associated disorders market size has grown strongly in recent years. It will grow from $22.13 billion in 2025 to $23.7 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to high prevalence of hpv infections, introduction of prophylactic hpv vaccines, growth in cervical cancer screening programs, increasing healthcare expenditure in oncology, rising public health awareness campaigns.What Is The HPV Associated Disorders Market Growth Forecast?
The hpv associated disorders market size is expected to see strong growth in the next few years. It will grow to $30.97 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to expansion of gender-neutral vaccination policies, advances in molecular diagnostics, increasing incidence of hpv-linked oropharyngeal cancers, improved access to healthcare in emerging economies, pipeline development of therapeutic hpv vaccines. Major trends in the forecast period include expansion of hpv vaccination programs, rising adoption of early screening and diagnostics, growing focus on non-invasive treatment options, increasing awareness of hpv-related cancers, shift toward combination prevention and treatment strategies.
Global HPV Associated Disorders Market Segmentation
1) By Indication: Cervical Intraepithelial Neoplasia (CIN), Cervical Cancer, Anal Intraepithelial Neoplasia (AIN), Anal Cancer, Genital Warts, Other Indications 2) By Therapy: Prevention, Treatment 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Cervical Intraepithelial Neoplasia (CIN): CIN 1, CIN 2, CIN 3 2) By Cervical Cancer: Squamous Cell Carcinoma, Adenocarcinoma 3) By Anal Intraepithelial Neoplasia (AIN): AIN 1, AIN 2, AIN 3 4) By Anal Cancer: Squamous Cell Carcinoma, Other Types 5) By Genital Warts: Condylomata Acuminata 6) By Other Indications: Oropharyngeal Cancer, Vulvar and Vaginal Cancers, Other HPV-Related ConditionsWhat Is The Driver Of The HPV Associated Disorders Market?
The increasing prevalence of HPV cases is expected to propel the growth of the HPV-associated disorders market going forward. HPV-associated disorders include benign verrucae vulgates, condylomas acuminata, and malignancies of the cervix, vulva, anus, and penis, as well as anogenital warts, recurrent respiratory papillomatosis, and anogenital and oropharyngeal cancers. HPV infection has a considerable prevalence worldwide, particularly among women. For instance, in June 2025, according to the Centers for Disease Control and Prevention, a US-based government agency, in the United States, approximately 13,000 women are diagnosed with cervical cancer annually, and around 4,000 succumb to the disease each year. Therefore, the increase in HPV cases is driving the growth of the HPV-associated disorders market.Key Players In The Global HPV Associated Disorders Market
Major companies operating in the hpv associated disorders market are AstraZeneca plc, F. Hoffmann-La Roche Ltd, Biocon Ltd, GlaxoSmithKline plc, Merck & Co Inc., Pfizer Inc., Sanofi S. A., Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Bayer AG, Eisai Co. Ltd., Genentech Inc., MSD Pharmaceuticals, Seqirus, Bavarian Nordic, Serum Institute of India, Moderna Inc
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global HPV Associated Disorders Market Trends and Insights
Major companies operating in the HPV associated disorders market are launching HPV vaccines to combat HPV-related diseases. HPV vaccines play a crucial role in public health by reducing the incidence of HPV-related diseases and promoting cervical cancer screening and prevention efforts. For instance, in January 2023, the Serum Institute of India, an India-based institute CERVAVAC, the first indigenously developed human papillomavirus (HPV) vaccine aimed at preventing cervical cancer in women. The vaccine uses L1 virus-like particles (VLPs) to stimulate an immune response without causing infection. This method effectively primes the immune system to recognize and combat HPV if exposed in the future.What Are Latest Mergers And Acquisitions In The HPV Associated Disorders Market?
In July 2025, Biological E, an India-based vaccine and pharmaceutical manufacturer, entered into a licensing and technology transfer agreement with Recbio to expand access to advanced preventive therapies. Through this partnership, Biological E aims to produce and commercialize Recbio’s recombinant 9-valent HPV (HPV9) vaccine, enhancing its ability to combat HPV-associated disorders by expanding access to advanced HPV prevention solutions in global markets. Recbio is a China-based biopharmaceutical company that develops innovative vaccines and biotechnological products, including the HPV9 vaccine.
Regional Insights
North America was the largest region in the HPV associated disorders market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.Need data for a specific geography? Request Regional Data
What Defines the HPV Associated Disorders Market?
The human papillomavirus-associated disorders market includes revenues earned by entities by plantar warts and flat warts. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the HPV Associated Disorders Market Report 2026?
The hpv associated disorders market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hpv associated disorders industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.HPV Associated Disorders Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $23.7 billion |
| Revenue Forecast In 2030 | $30.97 billion |
| Growth Rate | CAGR of 7.1% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Indication, Therapy, Distribution Channel |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. |
| Key Companies Profiled | AstraZeneca plc, F. Hoffmann-La Roche Ltd, Biocon Ltd, GlaxoSmithKline plc, Merck & Co Inc., Pfizer Inc., Sanofi S. A., Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Bayer AG, Eisai Co. Ltd., Genentech Inc., MSD Pharmaceuticals, Seqirus, Bavarian Nordic, Serum Institute of India, Moderna Inc |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |